ClinicalTrials.gg
CompletedNCT05747924FORTITUDEUpdated Jul 16, 2026

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 1/2 interventional study of AOC 1020 and Placebo in FSHD, FSHD1 and FSHD2, sponsored by Avidity Biosciences, Inc.. Completed at 17 sites in 3 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Enrollment
5th of 21
90 · median 51
Started
2023
with 1 other
Phase 1/2
8 of 32
none open now
Registered
22nd of 32
by date
Lead sponsor
3 of 32
Avidity Biosciences, Inc.

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 in phase 1/2, and was the 22nd registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Read the detailed description

AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2).

Cohort A comprises a placebo-controlled dose titration cohort (Cohort A1) which includes a nested single and multiple dose schedule. Cohort B comprises a placebo-controlled, nested single ascending dose (SAD)/multiple ascending dose (MAD) cohort (Cohort B1). Cohort C comprises a randomized, placebo-controlled, expansion cohort (Cohort C1). For each of Cohorts A, B, and C the study duration is 12 months as the active treatment period is approximately 9 months for Cohorts A \& B and approximately 10.5 months for Cohort C followed by a 12-week follow-up period for Cohorts A \& B and a 7-week follow-up period for Cohort C. Once participants have completed active treatment with follow-up through 12 months, they may have the option to participate in a planned open-label extension. If patients do not immediately roll over into the open-label extension study or decline participation, they will be followed for 18 weeks after their last dose of study medication.

03

Conditions studied

  • FSHD
  • FSHD1
  • FSHD2
  • FMD
  • FMD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Dystrophies, Facioscapulohumeral Muscular
  • Dystrophy, Facioscapulohumeral Muscular
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facio-Scapulo-Humeral Dystrophy
  • Atrophy, Facioscapulohumeral
  • Atrophies, Facioscapulohumeral
  • Facioscapulohumeral Atrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral
  • FSH Muscular Dystrophy
  • Landouzy Dejerine Dystrophy
  • Landouzy-Dejerine Muscular Dystrophy
  • Dystrophies, Landouzy-Dejerine
  • Dystrophy, Landouzy-Dejerine
  • Landouzy-Dejerine Syndrome
  • Muscular Dystrophy, Landouzy Dejerine
  • Progressive Muscular Dystrophy
  • FSH

Keywords

  • FORTITUDE
  • Avidity
  • Avidity Biosciences
  • AOC 1020
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • FSHD1 or FSHD2 diagnosis confirmed by documented genetic testing (testing provided by Sponsor)
  • Ambulatory and able to walk 10 meters (with or without assistive devices such as one cane, walking stick or braces)
  • At least 1 muscle region suitable for (testing provided by Sponsor)
  • Muscle weakness in both upper and lower body, as determined by Investigator

Exclusion criteria

Exclusion Criteria:

  • Pregnant or intends to become pregnant while on study, or active breastfeeding
  • Unwilling or unable to continue to comply with requirements
  • (BMI) >35.0 kg/m2 at Screening
  • History of muscle within 30 days of the screening biopsy or planning to undergo any nonstudy muscle biopsies over the duration of the study
  • History of bleeding disorders, significant keloid, or other skin or muscle conditions (e.g., severe muscle wasting) that, in the opinion of the Investigator, makes the participant unsuitable for serial muscle biopsy
  • Anticipated survival less than 2 years
  • Blood or plasma donation within 16 weeks of Study Day 1
  • Any to MRI
  • Any abnormal lab values, conditions or diseases that, in the opinion of the investigator or Sponsor, would make the participant unsuitable for the study or could interfere with participation or completion of the study
  • Treatment with any investigative medication within 1 month (or 5 half-lives of the drug, whichever is longer) of Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    AOC 1020 Regimen 1

    Cohort A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months

    Drug: AOC 1020

  • Experimental
    AOC 1020 Regimen 2

    Cohort B1: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months

    Drug: AOC 1020

  • Experimental
    AOC 1020 Regimen 3

    Cohort C: AOC 1020 Dose Regimen 3; Eight doses administered intravenously over approximately 10 months

    Drug: AOC 1020

  • Placebo comparator
    Placebo (Saline) Regimen 1

    Cohort A \& B: Placebo; Five doses administered intravenously over 9 months

    Drug: Placebo

  • Placebo comparator
    Placebo (Saline) Regimen 2

    Cohort C: Placebo; Eight doses administered intravenously over approximately 10 months

    Drug: Placebo

Interventions

  • AOC 1020 will be administered via intravenous (IV) infusion

  • DrugPlacebo

    Placebo will be administered via intravenous (IV) infusion

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (Cohorts A & B)

    Time frame: Through study completion, up to Day 365

  2. Change in plasma KHDC1L (Part C)

    Ratio to Baseline

    Time frame: Across months 3 to 12

Secondary outcomes

  1. Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)

    Observed maximum concentration

    Time frame: Through study completion; up to Day 365

  2. Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)

    Observed half-life

    Time frame: Through study completion; up to Day 365

  3. Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)

    Observed area under the curve

    Time frame: Through study completion; up to Day 365

  4. Muscle drug concentration (Cohorts A & B)

    Concentration of siRNA component in skeletal muscle

    Time frame: Day 120

  5. Change in circulating creatine kinase (Cohort C)

    Ratio to Baseline

    Time frame: Across months 3 to 12

07

Study locations

17 sites
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California San Diego
    San Diego, California 92093, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66205, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University
    Durham, North Carolina 27708, United States
  • Ohio State University
    Columbus, Ohio 43221, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • University of Washington
    Seattle, Washington 98104, United States
  • University of Ottawa
    Ottawa, Ontario K1Y 4E9, Canada
  • University College London
    London, WIT 7HA, United Kingdom
  • University of Sheffield
    Sheffield, S10 2TN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Mar 2026, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Feb 28, 2023
StartActual
Apr 4, 2023
Primary completionActual
Mar 18, 2026
CompletionActual
Mar 20, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05747924
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Apr 4, 2023
Primary completion
Mar 18, 2026
Completion
Mar 20, 2026
Last update
Jul 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AOC 1020

Start the discussion